STLN
Starling Oncology, Inc.Company Information
- Company Name
- Starling Oncology, Inc.
- CIK
- CIK0001799191
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- STLN: Nasdaq, DFPH: OTC, STLNW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8011
- SIC Description
- Services-Offices & Clinics of Doctors of Medicine
- Ticker
- STLN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-14
- Last sale
- 2026-08-21
- Shares purchased (TTM)
- 402,429
- Shares sold (TTM)
- 6,465,937
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 39,300,829
- Shares outstanding
- 103,031,493
- Ownership
- 38.14%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 23.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 41 | 30 | 34 | 28 | 30 | 40 | 50 | 47 | 36 | 36 | 33 | 28 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | 0 | 0 | 10 | 30 | 49 | 60 | ||||||
| Accounts Receivable Net Current | 66 | 58 | 59 | 60 | 56 | 49 | 48 | 55 | 54 | 59 | 42 | 48 | ||||||
| Other Receivables Net Current | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Inventory Net | 20 | 24 | 17 | 19 | 16 | 12 | 10 | 10 | 11 | 12 | 14 | 12 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 3 | 3 | 4 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | - | ||||||
| Assets Current | 129 | 117 | 113 | 110 | 105 | 107 | 112 | 116 | 116 | 141 | 143 | 153 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 11 | 11 | 11 | ||||||
| Operating Lease Right Of Use Asset | 21 | 23 | 22 | 23 | 24 | 24 | 26 | 27 | 27 | 27 | 29 | 29 | ||||||
| Intangible Assets Net Excluding Goodwill | 10 | 10 | 11 | 12 | 12 | 14 | 15 | 16 | 16 | 17 | 18 | 19 | ||||||
| Goodwill | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 178 | 168 | 165 | 164 | 160 | 164 | 173 | 179 | 180 | 205 | 209 | 218 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 60 | 48 | 43 | 36 | 35 | 29 | 24 | 25 | 16 | 21 | 14 | 13 | ||||||
| Operating Lease Liability Current | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | ||||||
| Accrued Liabilities Current | 27 | 24 | 21 | 23 | 23 | 23 | 21 | 15 | 13 | 18 | 14 | 13 | ||||||
| Liabilities Current | 95 | 79 | 71 | 66 | 65 | 60 | 52 | 47 | 35 | 46 | 35 | 32 | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 17 | 19 | 19 | 20 | 21 | 22 | 23 | 25 | 25 | 25 | 26 | 26 | ||||||
| Derivative Liabilities Noncurrent | 11 | 8 | 13 | 14 | 8 | 4 | 0 | 1 | 1 | 3 | 3 | 2 | ||||||
| Long Term Debt Noncurrent | 80 | 79 | 77 | 76 | 75 | 74 | 93 | 92 | 90 | 88 | 87 | 85 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Commitments And Contingencies | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities | 203 | 185 | 180 | 176 | 169 | 159 | 169 | 164 | 150 | 163 | 152 | 147 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 260 | 259 | 257 | 253 | 239 | 236 | 215 | 214 | 212 | 208 | 204 | 200 | ||||||
| Treasury Stock Common Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -284 | -274 | -271 | -264 | -247 | -230 | -211 | -198 | -182 | -166 | -146 | -127 | ||||||
| Stockholders Equity | -25 | -16 | -16 | -12 | -9 | 5 | 4 | 15 | 29 | 41 | 57 | 72 | ||||||
| Liabilities And Stockholders Equity | 178 | 168 | 165 | 164 | 160 | 164 | 173 | 179 | 180 | 205 | 209 | 218 | ||||||
| Variable Interest Entity Primary Beneficiary | - | 104 | 89 | 7 | 12 | 72 | 71 | 0 | -7 | 83 | 71 | 2 | ||||||
| Nonrecourse | - | 65 | 55 | - | - | - | 35 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 102 | 102 | 101 | 99 | 95 | 91 | 77 | 77 | 77 | 76 | 76 | 75 | ||||||
| Shares Outstanding | 100 | 100 | 99 | 98 | 93 | 89 | 76 | 76 | 75 | 74 | 74 | 74 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialStarling Oncology, Inc. (STLN) — SEC Financial Statements & Analysis
Starling Oncology, Inc. (STLN) is a services-offices & clinics of doctors of medicine company, incorporated in DE. Starling Oncology, Inc. trades on Nasdaq, OTC as: STLN, DFPH, STLNW. Starling Oncology, Inc. (STLN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, On profitability, Starling Oncology, Inc. posts a gross margin of 62.98%, an operating margin of -4.44%, a net margin of -4.94%, a Return on Equity (ROE) of 171.16%, a Return on Assets (ROA) of -17.16%, and a Return on Invested Capital (ROIC) of -74.72%. Per share, it reports EPS of $-0.28, diluted EPS of $-0.28, free cash flow per share of $-0.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 38.38% year-over-year, net income growth of -46.29% year-over-year, and EPS growth of -51.41% year-over-year. On the balance sheet, it maintains a current ratio of 1.36x, a quick ratio of 1.14x, working capital of $34.05M, a debt-to-equity ratio of -8.15x, a debt ratio of 1.14, an interest coverage ratio of -3.42x, free cash flow of $-3.29M (TTM), and net debt of $38.77M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.28
- ROE TTM
- 171.16%
- ROA TTM
- -17.16%
- Debt To Equity
- -8.15x
- Free Cash Flow TTM
- $-3.29M
- Net Revenue TTM Growth 1Y
- 38.38%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Starling Oncology, Inc. in?
Starling Oncology, Inc. (STLN) operates in the Services-Offices & Clinics of Doctors of Medicine industry.
What exchange does STLN trade on?
Starling Oncology, Inc. (STLN) trades on the Nasdaq, OTC.
Where is Starling Oncology, Inc. incorporated?
Starling Oncology, Inc. is incorporated in DE.
When was Starling Oncology, Inc. (STLN)'s most recent SEC filing?
Starling Oncology, Inc. (STLN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is STLN's EPS (earnings per share)?
Starling Oncology, Inc. (STLN)'s trailing twelve month EPS is $-0.28 as of 2026-06-30.
What is STLN's ROE (return on equity)?
Starling Oncology, Inc. (STLN)'s trailing twelve month Return on Equity (ROE) is 171.16% as of 2026-06-30.
What is STLN's ROA (return on assets)?
Starling Oncology, Inc. (STLN)'s trailing twelve month Return on Assets (ROA) is -17.16% as of 2026-06-30.
What is STLN's ROIC (return on invested capital)?
Starling Oncology, Inc. (STLN)'s trailing twelve month Return on Invested Capital (ROIC) is -74.72% as of 2026-06-30.